Company intelligence / Profile preview

Quinnova Pharmaceuticals

Jamison, Pennsylvania, United States

Ownership: Private
Employees: ~73
Development stage: Other

Overview

Quinnova has FDA-approved products on the market including NEOSALUS brand foam and cream, and Ecoza (econazole nitrate) topical foam for fungal infections

Therapeutic areas: DermatologyInfectious Diseases
Modalities: Small molecule
Industry: Biotech

Drug pipeline

3 assets

KPV peptide

Preclinical

2 more assets in the full pipeline.

Request access →

Partnerships

Amneal Enterprises (2010-2015 period)Exeltis (current parent through Everett Laboratories acquisition)

Beyond the preview

Go deeper on Quinnova Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Quinnova Pharmaceuticals.

Explore the full profile